A 
Alnylam Pharmaceuticals ALNY · USD
Health Care · Biotechnology · US listing · 🇺🇸 United States
Nasdaq-100
156.61
+0.43%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$3.71bn
FY2016FY2025
Net income
$313.7m
FY2016FY2025
Free cash flow
$465.4m
FY2016FY2025
Shareholders' equity
$789.2m
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71bn | $2.25bn | $1.83bn | $1.04bn | $844.3m | $492.9m | $219.8m | $74.9m | $89.9m | $47.2m |
| Gross profit | $3.04bn | $1.92bn | $1.52bn | $868.6m | $704.1m | $414.8m | $194.7m | $73.1m | $89.9m | $47.2m |
| Research and development | $1.32bn | $1.13bn | $1.00bn | $883.0m | $792.2m | $654.8m | $655.1m | $505.4m | $390.6m | $382.4m |
| Operating income | $501.6m | −$235.5m | −$312.3m | −$785.1m | −$710.7m | −$782.9m | −$939.4m | −$814.7m | −$500.1m | −$424.6m |
| Net income | $313.7m | −$278.2m | −$440.2m | −$1.13bn | −$852.8m | −$858.3m | −$886.1m | −$761.5m | −$490.9m | −$410.1m |
| Diluted earnings per share | 2.30 | -2.16 | -3.50 | -9.18 | -7.12 | -7.38 | -7.93 | -7.53 | -5.11 | -4.78 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $4.97bn | $4.24bn | $3.83bn | $3.55bn | $3.64bn | $3.41bn | $2.40bn | $1.57bn | $1.99bn | $1.26bn |
| Cash and short-term investments | $2.91bn | $2.69bn | $2.44bn | $2.19bn | $2.44bn | $1.87bn | $1.54bn | $1.08bn | $1.70bn | $942.6m |
| Total liabilities | $4.18bn | $4.17bn | $4.05bn | $3.70bn | $3.06bn | $2.39bn | $956.4m | $272.8m | $228.3m | $342.6m |
| Debt | $2.70bn | $2.47bn | $2.40bn | $1.02bn | $675.7m | $191.3m | — | $30.0m | $30.0m | $150.0m |
| Shareholders' equity | $789.2m | $67.1m | −$220.6m | −$158.2m | $588.2m | $1.02bn | $1.44bn | $1.30bn | $1.77bn | $920.2m |
| Shares outstanding | 136m | 129m | 126m | 123m | 120m | 116m | 112m | 101m | 96m | 86m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $524.1m | −$8.3m | $104.2m | −$541.3m | −$641.7m | −$615.0m | −$278.4m | −$562.6m | −$382.8m | −$307.7m |
| Capital spending | −$58.7m | −$34.3m | −$62.2m | −$72.1m | −$76.4m | −$70.4m | −$140.2m | −$126.9m | −$104.2m | −$64.6m |
| Free cash flow | $465.4m | −$42.6m | $41.9m | −$613.3m | −$718.1m | −$685.3m | −$418.6m | −$689.5m | −$487.0m | −$372.3m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29bn | $1.17bn | $1.10bn | $1.25bn | $773.7m | $594.2m | $593.2m | $500.9m |
| Gross profit | $992.7m | $956.1m | $829.3m | $1.05bn | $630.7m | $523.1m | $490.3m | $415.0m |
| Operating income | $231.4m | $268.6m | $234.4m | $368.0m | −$22.6m | $18.1m | −$155.1m | −$76.9m |
| Net income | $164.5m | $206.0m | $186.4m | $251.1m | −$66.3m | −$57.5m | −$83.8m | −$111.6m |
| Diluted earnings per share | 1.19 | 1.49 | 1.37 | 1.84 | -0.49 | -0.42 | -0.65 | -0.87 |
| Cash from operations | $75.0m | $70.0m | $163.0m | $325.0m | $153.0m | −$118.0m | −$94.0m | $43.0m |
| Capital spending | −$34.0m | −$21.0m | −$23.0m | −$12.0m | −$14.0m | −$8.0m | −$9.0m | −$4.0m |
| Free cash flow | $41.0m | $49.0m | $140.0m | $313.0m | $139.0m | −$126.0m | −$103.0m | $39.0m |
| Total assets | $5.56bn | $5.13bn | $4.97bn | $4.85bn | $4.57bn | $4.21bn | $4.24bn | $4.21bn |
| Cash and short-term investments | $3.31bn | $3.01bn | $2.91bn | $2.72bn | $2.86bn | $2.63bn | $2.69bn | $2.78bn |
| Debt | $1.06bn | $1.06bn | $1.05bn | $1.09bn | $1.07bn | $1.07bn | $1.07bn | $1.07bn |
| Shareholders' equity | $1.35bn | $1.08bn | $789.2m | $233.9m | $250.6m | $115.4m | $67.1m | $32.4m |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 53.0% | 49.8% | 56.9% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 83.2% | 83.2% | 83.3% | 83.8% |
| Operating margin | 4.5% | -9.4% | -22.9% | -49.8% |
| Net margin | 0.6% | -17.4% | -31.9% | -57.2% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 172.7 | -108.8 | -54.6 | -25.9 | -23.8 | -17.6 | -14.5 | -9.7 | -24.9 | -7.8 |
| Price to sales | 14.6 | 13.5 | 13.2 | 28.2 | 24.1 | 30.7 | 58.6 | 98.4 | 135.8 | 68.2 |
Market value over time
31 Oct 2016 to 18 Sept 2026, in USD
$3.05bn$33.12bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return | 66% | 27% | -20% | 18% | 42% | 20% | 76% | -46% | 189% | -12% |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.